// App-Quantinova.ai

: Cabozantinib in patients with locally advanced or metastatic urothelial cell carcinoma who have progressed after cisplatin-based chemotherapy and anti-PD-1/PD-L1 therapy or after anti-PD-1/PD-L1 therapy only.

Researchers

Presenter

  • Georg Bartsch

Principal Investigators

  • Christian Thomas

  • Igor Tsaur

  • Marco Schnabel

  • Axel Haferkamp

  • Stanislav Gorbulev

  • Christian Ruckes

  • Kai Kronfeld

Medical Centers

  • Department of Urology and Pediatric Urology, University of Mainz, Mainz, Germany

  • National Center for Tumor Diseases DKFZ, Heidelberg, Germany

  • Universitatsmedizin, Mainz, Germany

  • Markus Krankenhaus, Frankfurt Am Main, RI, Germany

  • Mainz, Germany

  • Department of Urology, Caritas Hospital St. Josef, University of Regensburg, Regensburg, Germany

Locations

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Bladder Cancer

  • Solid malignancies

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Cabozantinib

  • Cisplatin

Outcome

  • N/A

Study Design

  • Single Arm

  • Multicenteric

  • Cohort

Phase

  • II

Study Id's

  • NCT04066595

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved